At the moment there are a multitude of signals investors put to use to appraise stocks. Two of the less utilized signals are hedge fund and insider trading sentiment. Our researchers have shown that, historically, those …
INSIDER MONKEY · 11/27/2015
Myriad Genetics
Investors in Myriad Genetics, Inc. (Symbol: MYGN) saw new options become available today, for the January 2016 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MYGN
NASDAQ · 11/25/2015
Call Options
six have issued a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $41.31. Shares of Myriad Genetics (NASDAQ:MYGN) …
Ticker Report · 11/17/2015
Myriad Genetics
More from Bing News
The up-and-down gyrations and concern of a broader market correction are enough to scare even the hardiest traders. But if you think there’s nothing to be found in this kind of market, look no further than Myriad Genetics (MYGN). MYGN sports a rare ...
Investor Place · 9/2/2015
Trade-Ideas LLC identified Myriad Genetics ( MYGN) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Myriad Genetics as such a stock due to the following factors ...
The Street · 11/5/2015
Myriad Genetics (NASDAQ:MYGN) has earned an average rating of “Hold” from the sixteen analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a …
Intercooler · 11/15/2015
Myriad Genetics
Myriad Genetics (NASDAQ:MYGN)‘s stock had its “overweight” rating restated by investment analysts at Piper Jaffray in a report issued on Friday, MarketBeat reports. They currently have a $47.00 price objective on the stock, up from their prior price ...
Watch List News · 11/12/2015
So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case. MYGN currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Yahoo Finance · 10/20/2014
Myriad Genetics (NASDAQ:MYGN) was upgraded by Zacks from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, MarketBeat.Com reports. The brokerage presently has a $42.00 price target on the stock. · 10/17/2015
This molecular diagnostic company has witnessed 3 negative estimate revisions in the last 30 days. Yet, the Zacks Consensus Estimate has moved higher over the same period. This indicates strong trading potential for the company. So make sure to keep …
ZACKS · 8/13/2015